🔴 Incyte Corporation is trading 4.03% down today on apparent profit-taking despite a strong broader market

Incyte Corporation is trading 4.03% down today at $104.16 on apparent profit-taking as the move lacks a clear company-specific catalyst.

• The sharp intraday pullback appears disconnected from the broader market's strength, suggesting a delayed reaction to recent gains or stock-specific selling pressure.
• Recent corporate news remains fundamentally positive, highlighted by the June 14 release of supportive Phase 3 frontMIND data for tafasitamab.
• The decline stands in contrast to the day’s generally risk-on market tone, with no negative regulatory or clinical updates reported.